BioSpace News Archive

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s 1Q2023 unaudited condensed interim consolidated Financial Statements.

Belite Bio, Inc announced that it has priced an underwritten public offering of 2,000,000 American Depositary Shares, each representing one of its ordinary shares, and warrants to purchase 2,000,000 ordinary shares represented by ADSs, at a public offering price of $15.00 per ADS and accompanying warrant.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s 1Q2023 unaudited condensed interim consolidated Financial Statements.

Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has recommended olverembatinib, Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.

Hinge Bio, Inc., a privately-held biotechnology company, announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.